

PCR-Based Assay for Detection of *Neisseria meningitidis* Capsular Serogroups 29E, X, and Z

Désirée E. Bennett,¹ Robert M. Mulhall,¹ and Mary T. Cafferkey^{1,2*}

Epidemiology and Molecular Biology Unit, The Children's University Hospital,¹ and Department of Clinical Microbiology, Royal College of Surgeons in Ireland,² Dublin, Ireland

Received 31 October 2003/Returned for modification 16 December 2003/Accepted 23 December 2003

PCR-based assays for the identification of *Neisseria meningitidis* serogroups 29E, X, and Z by detection of specific regions of the *ctrA* gene are described. The specificities of these assays were confirmed using serogroups A, B, C, 29E, H, W135, X, Y, and Z and nongroupable meningococcal isolates.

Characterization of meningococci by serogroup is useful and convenient in investigation of disease outbreaks and vaccine effectiveness. Thirteen meningococcal serogroups are known based on capsular polysaccharide antigens of viable organisms (17, 21). PCR-based assays are routinely used for the detection and identification of serogroups A, B, C, W135, and Y (2, 4, 5, 8, 9, 12, 15, 16, 22, 25; M.-K. Taha and A. Fox, 7th Meet. Eur. Monit. Group Meningococci, abstr. P39-40, 2003). In Ireland, serogroup B, C, W135, and Y meningococci were responsible for 97% of cases diagnosed in 1997 to 2000, with group B predominating (M. Cafferkey, K. Murphy, M. Fitzgerald, and D. O'Flanagan, 6th Meet. Eur. Monit. Group Meningococci, abstr. P67-68, 2001), similar to the situations in other developed countries (17, 19); hence, only 3% of cases were caused by other serogroups. PCR-based assays are not available for the identification of serogroups 29E, X, and Z. It is possible that isolates designated as nongroupable are isolates of these serogroups that fail to express or poorly express the capsular phenotype while harboring the genetic material necessary for capsule production.

A limited number of cases of meningococcal disease (1%) due to serogroups 29E, X, and Z have been reported worldwide (7, 14, 20, 22). This low incidence is probably an underestimation. Strains of these three serogroups have been isolated in carriage studies, albeit also at low frequencies, with reported figures of 5.6 and 5.8% for serogroup 29E (1, 10), 2.1 and 3.8% for serogroup X (1, 10), and from 0.6 to 6.6% for serogroup Z (1, 3), with a median of 1.3% (7, 10, 13).

Here we report PCR-based assays for the rapid individual detection and identification of meningococcal serogroups 29E, X, and Z. The *ctrA* gene, exclusive to meningococci and forming part of the capsule biosynthesis locus, was chosen as the PCR target. The 3' end of the *ctrA* gene is highly conserved among meningococci irrespective of serogroup, but the 5' end varies. It is to this variable region that forward primers specific for serogroups 29E, X, and Z (Table 1) were designed (GenBank accession numbers AF520907, AY289931, and AF520909, respectively). These primers were used with a re-

verse primer (Table 1) described by Corless et al. (4) and demonstrated to amplify a region of the *ctrA* gene from all meningococcal serogroups (4, 11).

The specificity of these primers in amplifying the *ctrA* target from different meningococcal serogroups was tested by PCR. All meningococcal strains used were isolated from cases of disease or during a carriage survey (unpublished data). The serogroup of each isolate was determined by coagglutination and/or by direct slide agglutination. For each serogroup, separate PCRs were performed in 50- μ l volumes comprising 1 U of *Taq* DNA polymerase (Gibco-BRL/Life Technologies), 2.5 mM MgCl₂, 5 μ l of 10 \times buffer (1 \times buffer contains 10 mM Tris HCl [pH 9 at 25°C], 50 mM KCl, 0.1% Triton X-100), 1.5 mM (each) forward and reverse primer, and 0.2 mM deoxynucleoside triphosphates (dATP, dGTP, dCTP, and dTTP), to which 1 μ l of purified *N. meningitidis* DNA (100 to 300 ng) (Puregene DNA isolation kit; Gentra Systems, Minneapolis, Minn.) was added. Amplifications were carried out on a PTC 200 DNA Engine (MJ Research) thermal cycler, using the same parameters irrespective of serogroup, and involved, after an initial cycle of 95°C for 5 min, 35 cycles of denaturation at 94°C for 30 s, annealing at 62.5°C for 1 min, and extension at 72°C for 30 s. Following amplification, all reaction mixes were held at 4°C until 5 μ l of reaction mix was analyzed on a 3.5% (wt/vol) agarose gel containing 0.5 μ g of ethidium bromide/ml and viewed using UV light.

Amplification products of 667 bp were observed for serogroups 29E (primer *ctrA* 29EF2) and Z (primer *ctrA* ZF), and a product of 525 bp was observed for serogroup X (primer *ctrA* XF3). No cross-reactions were observed between the specific forward primer and isolates of either of the other serogroups or for representative strains of serogroups B, C, H, W135, and Y (including 10 serogroup B strains, 10 serogroup C strains, 2 serogroup H strains, 5 serogroup W135 strains, and 5 serogroup Y strains). With the *ctrA* XF3 primer, products were detected in two serogroup A strains but were of a different size (approximately 650 bp) from that observed with serogroup X strains. Compared to conventional serologic grouping, the assays correctly identified 12 of 12 serogroup X isolates, 4 of 4 serogroup Z isolates, and 2 of 2 serogroup 29E isolates. Therefore, the specificity of these primers for grouping strains of these serogroups was 100%.

To further evaluate these assays, we applied them to 37

* Corresponding author. Mailing address: The Epidemiology and Molecular Biology Unit, The Children's University Hospital, Temple Street, Dublin 1, Ireland. Phone: 353-1-878-4858. Fax: 353-1-878-4856. E-mail: m.cafferkey@tisch.ie.

TABLE 1. Primer sequences used in this study

Name	5'-3' sequence	Reference
<i>ctrA</i> 29EF2	ATTACGCTGACGGCATGTGGA	This study
<i>ctrA</i> ZF	TATGCGGTGCTGTTTCGCTATG	This study
<i>ctrA</i> XF3	GTCTTTGTATAAGGCCCAAG	This study
<i>ctrA</i> UR	TTGTCGCGGATTTGCAACTA	5

isolates for which the serogroups could not be identified by conventional methods (hence, not of serogroup A, B, C, H, W135, or Y) that were recovered as part of a carriage survey undertaken during the 2000-2001 epidemiological year (D. E. Bennett, A. D. Stack, and M. T. Cafferkey, unpublished data). Each of these isolates contained the *ctrA* gene. Of the 37, 11 yielded a product with the *ctrA* XF3/*ctrA* UR primers, 6 yielded a product with the *ctrA* ZF/*ctrA* UR primers, and 19 yielded a product with the *ctrA* 29EF2/*ctrA* UR primers. The three primer pairs failed to generate an amplification product with only 1 isolate; presumably this isolate represented another uncommon serogroup, for instance, serogroup I, K, or L (for which there are no antisera available).

This report demonstrates that these assays reliably distinguish meningococcal serogroups 29E, X, and Z from other serogroups, with the major benefit of identifying these among previously nongroupable isolates. Used in conjunction with the already available PCR-based identification assays (6, 8, 15), these new assays allow the characterization of all meningococcal serogroups currently known to be associated with disease and/or carriage worldwide. Furthermore, since these assays are PCR based, they could be applied to clinical samples for diagnostic purposes.

Although few cases of disease have been reported with these serogroups, temporal changes in disease-associated serogroups are well documented (23); hence, they may emerge as significant pathogens. Characterization of meningococci according to serogroup is important given that most available meningococcal vaccines are capsular polysaccharide based (18). The exact effects of widespread immunization as far as inducing changes in the population structure of meningococci are unknown, but it is likely to affect the phenomenon of capsule switching and also to select for strains of serogroups previously considered to be of limited pathogenicity, such as serogroups 29E, X, and Z (20, 24). It is probable that the observed replacement of serogroup A strains by serogroup X strains colonizing and causing disease in northern Ghana was a direct effect of the mass A/C polysaccharide vaccination campaigns of 1997 and 1998 (7). The emergent serogroup X strains were closely related to serogroup X strains already present but at a much lower abundance. For precisely this reason, the serogroups of all circulating meningococci should be identified and monitored, especially in countries in which widespread meningococcal vaccination has been introduced.

We are grateful to A. D. Stack for expert technical assistance and the staff at the Meningococcal Reference Unit (Manchester Public Health Laboratory Services, Withington Hospital, Manchester, United Kingdom) for confirming isolate serogroups.

REFERENCES

- Ala'Aldeen, D., K. Neal, K. Ait-Tahar, J. Nguyen-Van-Tam, A. English, T. Falla, P. Hawkey, and R. Slack. 2000. Dynamics of meningococcal long-term carriage among university students and their implications for mass vaccination. *J. Clin. Microbiol.* **38**:2311-2316.
- Borrow, R., H. Claus, M. Guiver, L. Smart, D. Jones, E. Kaczmarski, M. Frosch, and A. Fox. 1997. Non-culture diagnosis and serogroup determination of meningococcal B and C infection by a sialyltransferase (*siaD*) PCR ELISA. *Epidemiol. Infect.* **118**:111-117.
- Caugant, D., A. Hoiby, P. Magnus, O. Scheel, T. Hoel, G. Bjune, E. Wedge, J. Eng, and O. Froholm. 1994. Asymptomatic carriage of *Neisseria meningitidis* in a randomly sampled population. *J. Clin. Microbiol.* **32**:323-330.
- Corless, C., M. Guiver, R. Borrow, V. Edwards-Jones, A. Fox, and E. Kaczmarski. 2001. Simultaneous detection of *Neisseria meningitidis*, *Haemophilus influenzae*, and *Streptococcus pneumoniae* in suspected cases of meningitis and septicemia using real-time PCR. *J. Clin. Microbiol.* **39**:1553-1558.
- Diggle, M., K. Smith, E. Girvan, and S. Clarke. 2003. Evaluation of a fluorescence-based PCR method for identification of serogroup A meningococci. *J. Clin. Microbiol.* **41**:1766-1768.
- Dolan-Livengood, J., Y. Miller, L. Martin, R. Urwin, and D. Stephens. 2003. Genetic basis for nongroupable *Neisseria meningitidis*. *J. Infect. Dis.* **187**:1616-1628.
- Gagneux, S., A. Hodgson, T. Smith, T. Wirth, I. Ehrhard, G. Morelli, B. Genton, F. Binka, M. Achtman, and G. Pluschke. 2002. Prospective study of a serogroup X *Neisseria meningitidis* outbreak in northern Ghana. *J. Infect. Dis.* **185**:618-626.
- Guiver, M., and R. Borrow. 2001. PCR diagnosis, p. 23-40. In A. Pollard and M. Maiden (ed.), *Methods in molecular medicine*, vol. 67. Meningococcal disease: methods and protocols. Humana Press, Inc., Totowa, N.J.
- Guiver, M., R. Borrow, J. Marsh, S. Gray, E. Kaczmarski, D. Howells, P. Boseley, and A. Fox. 2000. Evaluation of the Applied Biosystems automated Taqman polymerase chain reaction system for the detection of meningococcal DNA. *FEMS Immunol. Med. Microbiol.* **28**:173-178.
- Jolley, K., J. Kalmusova, E. Feil, S. Gupta, M. Musilek, P. Kriz, and M. Maiden. 2000. Carried meningococci in the Czech Republic: a diverse recombining population. *J. Clin. Microbiol.* **38**:4492-4498.
- Jordens, Z., J. Williams, G. Jones, and J. Heckels. 2002. Detection of meningococcal carriage by culture and PCR of throat swabs and mouth gargles. *J. Clin. Microbiol.* **40**:75-79.
- Kaczmarski, E., P. Ragnathan, J. Marsh, S. Gray, and M. Guiver. 1998. Creating a national service for the diagnosis of meningococcal disease by polymerase chain reaction. *Commun. Dis. Public Health* **1**:54-56.
- Kellerman, S., K. McCombs, M. Ray, W. Baughman, M. Reeves, T. Popovic, N. Rosenstein, M. Farley, P. Blake, and D. Stephens. 2002. Genotype-specific carriage of *Neisseria meningitidis* in Georgia counties with hyper- and hyposporadic rates of meningococcal disease. *J. Infect. Dis.* **186**:40-48.
- Kyaw, M., S. Clarke, P. Christie, I. Jones, and H. Campbell. 2002. Invasive meningococcal disease in Scotland, 1994-1999, with emphasis on group B meningococcal disease. *J. Clin. Microbiol.* **40**:1834-1837.
- Lee, S.-O., S.-H. Ryu, S.-J. Park, J. Ryu, J.-H. Woo, and Y.-S. Kim. 2003. Meningococcal disease in the Republic of Korea Army: incidence and serogroups determined by PCR. *J. Korean Med. Sci.* **18**:163-166.
- Lewis, C., and S. Clarke. 2003. Identification of *Neisseria meningitidis* serogroups Y and W135 by *siaD* nucleotide sequence analysis. *J. Clin. Microbiol.* **41**:2697-2699.
- Maiden, M., and N. Begg. 2001. Overview: epidemiology, surveillance and population biology, p. 121-130. In A. Pollard and M. Maiden (ed.), *Methods in molecular medicine*, vol. 67. Meningococcal diseases: methods and protocols. Humana Press, Inc., Totowa, N.J.
- Morley, S., and A. Pollard. 2002. Vaccine prevention of meningococcal disease, coming soon? *Vaccine* **20**:666-687.
- Pollard, A., D. Scheifele, and N. Rosenstein. 2001. Epidemiology of meningococcal disease in North America, p. 341-357. In A. Pollard and M. Maiden (ed.), *Methods in molecular medicine*, vol. 67. Meningococcal disease: methods and protocols. Humana Press, Inc., Totowa, N.J.
- Poolman, J., P. van der Ley, and J. Tommassen. 1995. Surface structures and secreted products of meningococci, p. 21-34. In K. Cartwright (ed.), *Meningococcal disease*. John Wiley & Sons, Ltd., Chichester, England.
- Popovic, T., G. Ajello, and R. Facklam. 1999. Laboratory manual for the diagnosis of meningitis caused by *Neisseria meningitidis*, *Streptococcus pneumoniae*, and *Haemophilus influenzae*. [Online.] World Health Organization, Geneva, Switzerland. <http://www.who.int/emc-documents/meningitis/docs/whocdscsredc997.pdf>.
- Probert, W., S. Bystrom, S. Khashe, K. Schrader, and J. Wong. 2002. 5' exonuclease assay for detection of serogroup Y *Neisseria meningitidis*. *J. Clin. Microbiol.* **40**:4325-4328.
- Stephens, D. 1999. Uncloning the meningococcus: dynamics of carriage and disease. *Lancet* **353**:941-942.
- Swartley, J., A. Marfin, S. Edupuganti, L.-J. Liu, P. Cieslak, B. Perkins, J. Wenger, and D. Stephens. 1997. Capsule switching of *Neisseria meningitidis*. *Proc. Natl. Acad. Sci. USA* **94**:271-276.
- Taha, M.-K. 2000. Simultaneous approach for nonculture PCR-based identification and serogroup prediction of *Neisseria meningitidis*. *J. Clin. Microbiol.* **38**:855-857.